Established medicines need renewed focus
Christopher Hähner of Good Healthcare Pharma says established medicines need active lifecycle management despite the industry's innovation focus.
Bayer CEO Bill Anderson warns of Germany’s competitiveness gap
Bayer CEO Bill Anderson says high energy costs and bureaucracy put Germany at a disadvantage. He also warns of fertilizer risks linked to Hormuz disruptions.
Boehringer Ingelheim halts planned investment in Germany
Boehringer Ingelheim is halting €900 million in planned investment in Germany for 2027 to 2030, citing policy-related and location factors.
Italy probes Biogen over Tysabri test and market abuse claims
Italy’s AGCM is investigating Biogen over alleged market abuse tied to anti-JCV testing for Tysabri, with potential effects on Sandoz.
Biogen completes acquisition of Apellis Pharmaceuticals
Biogen has completed its acquisition of Apellis. The deal adds SYFOVRE and EMPAVELI and is positioned to support Biogen’s nephrology expansion.
Health system under pressure: sustainability as a lever for prevention
At WeACT Con, experts discussed how prevention and environmental health can reduce risks and help stabilize healthcare, from funding ideas to guidance.
Bedrocan flower to be offered as Becanex PIEX raw extract for compounding
Bedrocan and Becanex plan PIEX Bedrocan 70% THC as a raw extract for pharmacy compounding, with shipments expected to start in summer 2026.
Vetter breaks ground on new production site in Saarlouis
Vetter has started construction of a new production site in Saarlouis. The first phase includes a 50,000 m² building, with start-up planned for 2031.
Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1bn
Angelini Pharma has agreed to buy Catalyst for $4.1bn in cash, entering the U.S. market. The companies expect the deal to close in Q3 2026.
UEFA appoints Haleon as first medicine and health partner
UEFA has named Haleon its first partner for medicine and health. The multi-year collaboration focuses on evidence-based pain management in football.
Daiichi Sankyo honors patient initiatives with O-Mamori Award 2026
Daiichi Sankyo presented the O-Mamori Award 2026 in Berlin. Eight cardiology and oncology patient initiatives share 30,000 euros in prize money.
Gilead Extends Tender Offer for Arcellx
Gilead has extended its tender offer to acquire Arcellx until April 24, 2026. The offer remains $115 per share in cash plus a CVR.
IQVIA: German pharma market up in value in 2025, volumes slightly down
IQVIA reports 5.7% sales growth in Germany’s pharma market in 2025, while volumes slipped by 0.7%. In pharmacies, Rx grew faster than OTC.
Gilead to acquire Ouro Medicines for clinical BCMAxCD3 program
Gilead Sciences plans to buy Ouro Medicines for up to $2.175bn, adding OM336, a clinical BCMAxCD3 T cell engager for autoimmune diseases.
Hims & Hers shifts US weight loss strategy with Novo Nordisk deal
Hims & Hers is refocusing its US weight loss business and teaming up with Novo Nordisk, prioritizing access to a wider set of FDA-approved GLP-1 drugs.
Sandoz launches azelastine/fluticasone nasal spray in Germany and Switzerland
Sandoz has launched an azelastine/fluticasone nasal spray in Germany and Switzerland, expanding access to a fixed-dose allergy treatment option.
Sandoz partners with Samsung Bioepis on up to five biosimilars
Sandoz and Samsung Bioepis agreed to collaborate on up to five biosimilar assets, starting with an early-stage vedolizumab biosimilar program.
BC Partners and Bpifrance complete acquisition of Biogaran
BC Partners and Bpifrance have completed the acquisition of Biogaran from Servier. Erick Roche is set to become CEO by the end of March 2026.
Hikma reports revenue and core profit growth, launches buyback and reshuffles leadership
Hikma posted 2025 revenue and core profit growth, lifted its dividend and announced a US$250m share buyback plus immediate leadership changes.
Esperion to acquire Corstasis to add Enbumyst to its CV portfolio
Esperion has signed a definitive deal to acquire Corstasis. The transaction adds Enbumyst, an FDA-approved bumetanide nasal spray for edema.